Sorafenib in patients with refractory or recurrent multiple myeloma

• Verfasst von: Yordanova, Anna [VerfasserIn]
• Verfasst von: Hose, Dirk [VerfasserIn]
• Verfasst von: Neben, Kai [VerfasserIn]
• Verfasst von: Witzens-Harig, Mathias [VerfasserIn]
• Verfasst von: Raab, Marc-Steffen [VerfasserIn]
• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Titel: Sorafenib in patients with refractory or recurrent multiple myeloma
• Verf.angabe: Anna Yordanova, Dirk Hose, Kai Neben, Mathias Witzens-Harig, Ines Gütgemann, Marc-Steffen Raab, Thomas Moehler, Hartmut Goldschmidt and Ingo G.H. Schmidt-Wolf
• E-Jahr: 2013
• Jahr: 15 March 2013
• Umfang: 4 S.
• Teil: volume:31
• Teil: year:2013
• Teil: number:4
• Teil: pages:197-200
• Teil: extent:4
• Fussnoten: Gesehen am 26.07.2021
• Titel Quelle: Enthalten in: Hematological oncology
• Ort Quelle: New York, NY [u.a.] : Wiley Interscience, 1983
• Jahr Quelle: 2013
• Band/Heft Quelle: 31(2013), 4, Seite 197-200
• ISSN Quelle: 1099-1069
• DOI: doi:10.1002/hon.2043
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: multiple myeloma
• Sach-SW: phase II clinical trial
• Sach-SW: recurrent
• Sach-SW: refractory
• Sach-SW: sorafenib
• K10plus-PPN: 1764357361

Abstract

Sorafenib is a small molecular inhibitor of several tyrosine protein kinases, including vascular endothelial growth factor receptor, platelet-derived growth factor receptor and rapidly accelerated fibrosarcoma kinases, targeting signal transduction and angiogenic pathways. It is approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma. The objectives of this prospective phase II trial were to assess the activity and tolerability of sorafenib in patients with recurrent or refractory myeloma. In total, 11 patients were enrolled. Patients received 2 × 200 mg of sorafenib orally twice daily until completing 13 full cycles or disease progression. Of the side effects, 8.8% grade 3 and 1.1% grade 4 occurred. Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24.4 months and 6.9 month, respectively. Further clinical investigations are recommended to investigate sorafenib single agent activity in myeloma subgroups with ras-/BRAF-/vascular endothelial growth factor receptor pathway activation and combination therapy approaches.